Peptech looks towards positive second half result in shareholder address
16 July, 2002 by Tanya HollisSydney company Peptech is hinging its hopes for a positive second half result on the issuing of US patents for its anti tumour nectrotising factor.
Interpret GM polls with caution: NZ academic
16 July, 2002 by Tanya HollisPolls claiming to illustrate community views on genetic modification should be interpreted with caution because they did not always take into account a person's knowledge of the topic, a New Zealand academic has warned.
Genesis R&D to study plant hormones
16 July, 2002 by Melissa TrudingerNew Zealand based Genesis Research and Development Corporation will get $NZ6 million from the Foundation for Research Science and Technology to discover and investigate new plant hormones and signalling processes.
Qld teams with US researchers in drought crop project
16 July, 2002 by Melissa TrudingerCollaborative agreements between researchers at the Queensland Department of Primary Industries and three major US universities - Texas A&M University, Texas Tech and the University of Missouri - could lead to development of drought resistant crops.
Get planning, physics head tells synchrotron users
15 July, 2002 by Melissa TrudingerPotential users of Australia's national synchrotron need to start planning now, according to Sir Peter Williams, president of the UK Institute of Physics and proponent of the synchrotron project.
ResMed shrugs off a nervous market
15 July, 2002 by Tanya HollisDespite being regarded as one of Australia's top three listed biotech stocks, sleep disorder specialist ResMed would probably rather forget 2002.
Nasal nerve cells used in spinal repair in world first
12 July, 2002 by Pete YoungThe world's first clinical trial into repairing damaged spinal cords using transplanted nasal nerve cells now underway in Queensland could have global significance.
VosTech's Brightsun acquisition turns up the WA biotech heat
12 July, 2002 by Melissa TrudingerVosTech, a technology investment company based in Perth, is planning to enter the biotechnology market by acquiring animal biotechnology company Brightsun and its associated equity interests in CSIRO spin-off Vectogen and Murdoch University start-up Paragen.
New Zealand feature: election result key to NZ biotech
12 July, 2002 by Tanya HollisWith New Zealand's general election imminent, many in the biotechnology industry believe the outcome could determine the sector's future.
New Zealand feature: primary industry backs NZ biotech
12 July, 2002 by Melissa TrudingerIf biotechnology is as old as agriculture, then biotechnology in New Zealand has been around for as long as the nation. New Zealand is a country that relies on its strengths in its primary industries - dairying and sheep, horticulture and forestry.
Amrad abandons hep B compound after poor trials
11 July, 2002 by Tanya HollisAmrad Corporation's horror year plumbed new depths today when the company revealed poor results had led it to abandon its chronic hepatitis B compound.
Compumedics revises revenue figure, shares drop
11 July, 2002 by Tanya HollisSleep device developer Compumedics has flagged a 10 per cent reduction in its forecast sales for the year, triggering a share price slide.
Which genes make the best baked dinner?
11 July, 2002 by Melissa TrudingerA project at the South Australian Research and Development Institute (SARDI) is focusing on the qualities that make lamb tender and tasty.
Going for funding? Get a cash parachute, says Alchemia CEO
11 July, 2002 by Pete YoungBiotech companies in the midst of new funding rounds should build an extra cushion of cash into their requests, warns Alchemia CEO Tracie Ramsdale.
Strong US sales for Genetic Solutions
10 July, 2002 by Pete YoungTwo ex-CSIRO scientists who have spent four years quietly commercialising Australian expertise in livestock DNA testing are in the midst of a US sales boom.
